{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:43:24Z","timestamp":1777063404730,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T00:00:00Z","timestamp":1309219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single\u2010agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia\/small lymphocytic lymphoma (tCLL\/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25\u2003mg\/d. The overall response rate (ORR) was 46%, with a median response duration of 12\u00b78\u2003months after a median follow\u2010up of 5\u00b76\u2003months. Median progression\u2010free survival was 5\u00b74\u2003months. Among patients with tFL, ORR was 57%, with a median response duration of 12\u00b78\u2003months. None of the patients with tCLL\/SLL responded to lenalidomide monotherapy. The most common grade 3\/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08781.x","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T12:58:18Z","timestamp":1309438698000},"page":"477-481","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non\u2010Hodgkin lymphoma of distinct histological origin"],"prefix":"10.1111","volume":"154","author":[{"given":"Myron S.","family":"Czuczman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Polikoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Pietronigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annetti","family":"Ervin\u2010Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.532"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.055"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05755.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_7_10_1","first-page":"2616","article-title":"Lenalidomide enhances anti\u2010tumor effect of {gamma}{delta} T cells against mantle cell lymphoma","volume":"112","author":"Gaidarova S.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901166106"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802270902"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2010.01.010"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11201110-000000000-00000"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600757894"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903515192"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn657"},{"key":"e_1_2_7_19_1","first-page":"4459","article-title":"Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory\/relapsed transformed lymphoma","volume":"112","author":"Ramadan K.M.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1693"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5477"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07166.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11238"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8513"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00107-X"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08781.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08781.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:27:22Z","timestamp":1697412442000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08781.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08781.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08781.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,28]]},"assertion":[{"value":"2011-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}